Figure 1 (Zaltrap 01)
Zaltrap Solution, Concentrate
Product Images NDC 0024-5841
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 3 technical images submitted to the FDA as part of the official labeling for Zaltrap (NDC 0024-5841). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Sanofi-aventis U.s. Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Principal Display Panel (100 mg/4 mL Vial Carton)
The text is a set of instructions and details related to Zaltrap medication. It is administered through intravenous infusion only and should not be given by other routes. It is hyperosmotic and must be diluted before use. The patient is advised to discard any unused portion, and the medication should be stored refrigerated at 2-8°C and protected from light. The package insert provides information about dosage and administration. It contains 100mg of Snliawents US uc.*
Principal Display Panel (200 mg/8 mL Vial Carton)
ZALTRAP (ziv-aflibercept) is an injection for intravenous infusion only. Each vial contains 200 ml of zivaflibercept in a solution of 25 mg/ml. It is hyperosmotic and must be diluted. The medication is intended for intravenous use only, and the unused portion should be discarded. It is important to store it at refrigerated temperatures (36-46°F) and protect it from light. The dosage and administration are outlined in the package insert. ZALTRAP is a registered trademark of Regeneron Pharmaceutical Inc.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
